{
  "ticker": "NSB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959961",
  "id": "02959961",
  "pages": 8,
  "price_sensitive": true,
  "date": "20250619",
  "time": "0926",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kwwvzvqfc8yn.pdf",
  "summary": "**Key Material Information from Announcement:**  \n\n- **Clinical Trial Results for StemSmart\u2122 in GVHD:**  \n  - **Phase I Trial (Adults):**  \n    - 58% complete response, 33% partial response in steroid-refractory acute GVHD.  \n    - 55% 3-year survival vs. 15-20% expected.  \n    - No infusion-related toxicities.  \n  - **Compassionate Use (Children):**  \n    - 90% response rate (6 acute, 4 chronic GVHD cases).  \n    - All children survived to 12 months; 3 chronic GVHD patients alive >6 years post-treatment.  \n\n- **Market Opportunity:**  \n  - GVHD treatment market: **$2.55B (2023), projected $5.31B (2032)**.  \n  - Other addressable markets: Crohn\u2019s disease ($13.8B by 2026), kidney transplant ($7.2B by 2030).  \n\n- **Phase II Trial Limitation:**  \n  - No survival benefit for **new-onset acute GVHD** (early trial termination due to futility).  \n\n- **Acquisition Update:**  \n  - Pending acquisition of StemSmart\u2122 from Isopogen WA, subject to conditions.  \n\n**Omitted:** Non-material operational details, forward-looking statements, and trial methodology.",
  "usage": {
    "prompt_tokens": 5244,
    "completion_tokens": 287,
    "total_tokens": 5531,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T23:31:09.492976"
}